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6INTRODUCTION
Cardiovascular disease is the leading cause of death among women, regardless of race or 
ethnicity,  and causing the deaths  of 1 in 3 women; this  amounts to  more deaths from heart  
disease  than  from  stroke,  lung  cancer,  chronic  obstructive  lung  disease,  and  breast  cancer 
combined. 
Despite these sobering statistics and estimates that a 40-year-old woman has a lifetime 
risk of cardiovascular disease of 32 percent, and although awareness of cardiovascular disease as 
the  leading  cause  of  death  has  increased,  still  only  about  55  percent  of  women  identify 
cardiovascular disease as their greatest health risk.
 Although mortality from heart disease has declined gradually among men since 1979 (by 
30 to 50 percent), mortality from heart disease in women has increased during that same period. 
For coronary heart disease in specific, mortality rates have fallen for both men and women over 
this time period, but much more rapidly in men than women. A greater proportion of women (52 
percent) than men (42 percent) with myocardial infarction die of sudden cardiac death before 
reaching  the  hospital,  and  two  thirds  of  women  who  suffer  a  myocardial  infarction  never 
completely recover. Thus, understanding even subtle differences between men and women in 
development or progression of cardiovascular disease, use of proven therapies, and response to 
therapy is paramount.
Experts in industrialized societies have long recognized that the first presentation with 
coronary  heart  disease  occurs  approximately  10  years  later  among  women  than  men,  most 
commonly after menopause.
7 The worldwide  interheart Study, a large cohort study of more than 52,000 individuals 
with myocardial infarction, first demonstrated that this approximate 8- to 10-year difference in 
age of onset among men compared with women holds widely around the world, across various 
socioeconomic, climatic, and cultural environments.
Although  coronary  artery  disease  in  general  manifests  earlier  in  less  well-developed 
countries, the approximate 8 to 10 year age gap in time of onset between men and women is  
universal. Despite this delay in onset, mortality from coronary heart disease is increasing more 
rapidly among women than men in both the developed and developing world.
                          
                                   
8AIM OF THE STUDY
1. To  study  the  various  presenting  features  of  ST  Elevation  Myocardial  Infarction 
(STEMI) in female pts
2. To identify important risk factors of ST Elevation Myocardial Infarction (STEMI) in 
our study population.
     
9Review of literature
OVERVIEW:
Cardiovascular mortality continues at similar or increasing rates for women, whereas it is 
decreasing in men. Evidence based guidelines have been published following an expert panel 
review of the literature for the prevention of coronary artery disease in women(1).The importance 
of  coronary  artery  disease  and  its  prevention  in  women  is  gradually  receiving  increased 
physician and public attention. Yet, an online survey of primary care physicians, gynaecologists 
and cardiologists (2)  found that fewer than 20% of physicians aware the more women than men 
die annually of coronary artery disease.
In  addition,  coronary  artery  disease  in  women  is  a  formidable  problem  because  of 
difficulties in diagnosis and increased mortality and morbidity associated with coronary artery 
disease events at all ages. In the middle years, coronary artery disease is associated with multiple 
risk factors,  generally more in  women than men of  the same age.  Intermediate-risk women, 
defined  by Framingham criteria,  were  more  likely  to  be  defined  as  low risk  by  physicians 
surveyed in 1997.
FEMALE GENDER SPECIFIC ISSUES:
HYPERTENSION:
The  prevalence  of  hypertension  increases  with  advancing  age;  and  because  life 
expectancy is greater for women than men, there are more elderly women with hypertension (3). 
Generally, women are more likely to have controlled blood pressure than men. However, sex 
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differences in autonomic nervous system may explain difficulties in blood pressure modulation 
in some premenopausal women when exposed to stress or vasoactive substance drugs (4). 
Both systolic and diastolic blood pressures have been found in population, cohort and 
treatment studies to predict  coronary events.  Framingham data revealed that a systolic blood 
pressure >180,  the annual  incidence of  coronary artery disease (angina,  coronary deficiency, 
Myocardial Infarction or death from these diagnoses) in women older than age 65 years of age is 
>30%, whereas for men older than age 65 years of age, it is approximately 50 percent (5). In other 
epidemiologic  studies,  higher  diastolic  blood  pressure  also  predicts  greater  rates  of  clinical 
coronary artery disease (6).
Although treatment trials have also documented that lower blood pressure decreases the 
incidence of a first Myocardial Infarction   and sudden death, this effect has been less dramatic  
than decrease in stroke occurrence with blood pressure control. Especially when older subjects 
were included in clinical trials, the benefit of treating hypertension to prevent coronary events 
received greater recognition.
Gender  specific  information  about  pharmacological  therapy  of  hypertension  with 
angiotensin-converting enzyme (ACE) inhibitors and thiazides continues to evolve.
ACE inhibitors should be used cautiously in women of reproductive age as teratogenic 
effects have been documented in the first as well as second trimester (7). Potentially fertile women 
must understand the potential risk to the fetus before initiating therapy. Infants with only first 
trimester  ACE  inhibitor  exposure  had  increased  risk  of  cardiovascular  and  central  nervous 
system malformations compared with infants not exposed to antihypertensive medications; other 
antihypertensive  medications  did  not  increase  risk  for  congenital  malformations.  Cough, 
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common side effect of ACE inhibitors, occurred substantially more frequently in women than in 
men (8).
Thiazides are preferred first in the treatment of hypertension in women as well as men 
and are also beneficial for bone health. Epidemiological studies have documented a reduction of 
approximately one third in hip fracture with the use of thiazide diuretics. In randomized, double-
blind, placebo trial, thiazides were associated with preservation of hip and spine bone mineral 
density.
LIPIDS :
 There are sex difference in lipoprotein profiles and impact of lipids on cardiovascular 
(CV) risks (9). Many experts consider HDL (high density lipoprotein) more predictive for women 
than any other lipoprotein component, with the stronger correlation between low HDL levels and 
coronary artery disease events. 
LDL (low density lipoprotein) levels increase with increasing age for both women and 
men and especially important in women. In fact, one group of researchers suggest that enlarged 
waist (>88cm) combined with elevated triglycerides (>1.45mmol/L) best prospectively identified 
postmenopausal women at risk followed over 8 years (10).
Although  secondary  prevention  with  pharmacologic  treatment  for  hyperlipidemia 
decreases  coronary artery disease  events  in  women  as  well  as  men,  these  agents  are  under 
prescribed  for  women  after  myocardial  infarction  and  target  treatment  levels  are  often  not 
reached. Primary prevention trials  for hyperlipidemia in women with hydroxy-methylgluteryl 
coenzyme A (HMG- CoA) reductase inhibitors on careful review to do document evidence of 
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benefit with approximately 3 to 6 years of follow up, perhaps related to low events (9). With the 
latest  cholesterol treatment guidelines, diabetic women are candidates for primary prevention 
with aggressive treatment of lipid abnormalities.
DIABETES:
Diabetic individuals have higher mortality rates from coronary artery disease than non 
diabetics  (11-!5). In the last decade, coronary artery disease mortality rates have increased by 23 
percent in diabetic women, whereas they have decreased by 27 percent in non diabetic women. 
This is in comparison to diabetic men, where mortality rates have declined by 13 percent; but  
they have decreased by 36 percent in non diabetic men.
 A prospective 25 year follow up from Scotland revealed highest rates among those with 
both diabetes and known coronary artery disease with hazard ratios especially high for women 
1.97 compared with women neither risk factor(12). The higher coronary artery disease risk for 
diabetic women has been noted in multiple population studies. It has been postulated that sex 
differences  in endothelial  function,  especially endothelial  dependent  vasodilation may play a 
patho physiologic role  (14). Diabetic women have coronary artery disease rates similar rates to 
those of diabetic men, so the female advantage is lost.
Diabetes confers substantial increased relative risk of first incident and admission for MI 
for women compared with age to sex matched controls younger than age 65 years over 20 years 
follow up in Copenhagen City heart Study (13). 
Diabetic  women  also  have  higher  in-hospital  mortality  after  MI  and  an  increased 
incidence of congestive heart failure (CHF) than do diabetic men. Diabetic women and men with 
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hypertension  have  especially  high  rates  of  coronary  artery  disease(11,15).  Women  and  men 
generally have similar incidence rates of diabetes, but more women become hypertensive with 
increasing age.
Lipid abnormalities are common in diabetic patients. At the time of diagnosis off type II 
diabetes, women have substantially lower high density lipoprotein (HDL) cholesterol than age-
matched non diabetic women (17). Other lipid abnormalities are also present, including elevated 
triglycerides. Subgroup analysis of diabetic diabetic patients treated with hydroxy-methylgluteryl 
coenzyme A (HMG- CoA) reductase inhibitors documented improved lipoprotein patterns with 
treatment and fewer coronary artery disease events (11).
Women  at  risk  for  developing  diabetes  include  obese  women  and  those  who  have 
experienced gestational diabetes. Greater weight is associated with greater insulin resistance as 
well as a higher rate of glucose intolerance. Even a moderate increase in physical activity and 
avoiding weight gain decreases the risk of developing diabetes (11).
METABOLIC SYNDROME:
The metabolic syndrome was defined in the Third Report of the National Cholesterol 
Education  Program  Expert  Panel  On  Detection,  Evaluation  and  Treatment  of  High  Blood 
Cholesterol  (18) to  include  obesity,  glucose  intolerance,  hypertension  and  lipid  abnormalities 
occurs in women and men at greater rates with increasing age; tobacco exposure during 12 to19 
years of age dramatically increases the risk of having the metabolic syndrome (19). 
Polycystic ovarian syndrome (PCOS) with increased androgens , lower HDL and higher 
triglycerides and higher rates of coronary artery disease may affect as many as 10 to 20 percent  
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of women of child  bearing age(20,21).  In a retrospective chart  review of PCOS, patients at  an 
endocrine  clinic  also  had a  43 percent  prevalence  of  the metabolic  syndrome (twice  rate  of 
metabolic syndrome for age-matched women without PCOS) once assessed (22). Pharmacologic 
and  lifestyle  interventions  may improve  prognosis.  Aggressive  management  of  tobacco  use, 
lipoprotein  abnormalities  and  hypertension  is  beneficial.  Regular  exercise  can  also  improve 
glucose and blood pressure control as well as insulin resistance (11).
OBESITY :
The prevalence of obesity has been steadily increasing with a doubling among Americans 
older than age 20 years from 1980 to 2002. Ethnic and racial differences in obesity are more 
marked among women than men. Racial differences in BMI as well as glycosylated hemoglobin 
start in childhood with black and Mexican American girls having less favorable profiles than 
white girls (23).
 Obesity is linked to multiple cardiac risk factors (including insulin resistance, diabetes, 
hypertension and hyperlipidemia) and independently associated with coronary artery event rates 
(24). The pattern of weight distribution is also predictive of coronary events, with more events 
among women with the apple shape, with a greater central or abdominal girth, than among those 
with  the  pear  shape,  with  more  weight  in  hips  and buttocks.  A greater  waist  circumference 
increases health risk regardless of body mass index (BMI) (25).
Increased physical activity or limited weight loss is associated with a decreased risk of 
coronary artery disease  events.  Behavioral  interventions  to  decrease  weight  have  been  most 
successful when there is a physical activity component. A study of obese twins revealed the lack 
of physical activity correlated with the more obese twin. In the Nurses’ Health Study, both BMI 
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>25 and physical activity were important predictors of coronary artery disease in 20 years follow 
up. Although new pharmacologic treatments for obesity have been developed, many have been 
documented to be hazardous.
PHYSICAL ACTIVITY AND EXERCISE:
 Women’s physiologic response to exercise includes a lower work capacity and oxygen 
uptake than men (26). This occurs because women’s cardiac output is increased by raising heart 
rate. Men, in comparison, accomplish an increase in cardiac output by increasing stroke volume.
Physical activity is  important for primary and secondary prevention.  Physical activity 
data collection has focused on leisure activity and excluded house work and child care. Leisure-
time activity reports  may greatly underestimate the actual amount of energy expended daily, 
especially by women.
 In  observing  women  health  professionals  over  an  average  of  5  years,  women  who 
walked at least 1 hour each week had half the coronary artery disease rate as women who did not 
walk regularly. Both women and men benefit from referral to cardiac rehabilitation programs 
after MI; however, fewer women than men are referred for cardiac rehabilitation.
MENOPAUSE AND HORMONAL THERAPY:
 The importance of the menstrual cycle and menopause as risk factors for coronary artery 
disease is still being defined. Women with early menopause after gynaecologic survey have been 
considered  at  higher  risk  for  coronary  artery  disease  and  osteoporosis  on  the  basis  of  less 
hormonal exposure. Although population surveys suggested hormonal therapy after menopause 
may decrease  the  risk  of  coronary artery disease,  the  women  using  hormones  reported  less 
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tobacco exposure, greater levels of exercise, and readier access to medical care; they also tended 
to be healthier and wealthier.
The Women’s health initiative (WHI), a prospective randomized clinical trial of women 
50 to  79 years  of  age,  revealed the  combination  of  estrogen and progestin  after  menopause 
increases coronary artery disease risk (27); and estrogen alone in women without uterus does not 
decrease coronary artery disease risk. Estrogen alone in women with a uterus is contraindicated 
because of the associated increased risk of endometrial cancer.
 In the Women’s health initiative (WHI) subgroup analysis of women ages 50 to 59 years 
with  7-year  follow  up  conjugated  equine  estrogen  also  was  not  protective.  In  contrast  the 
observational Nurses’ Health Study noted that women beginning hormonal therapy soon after 
menopause had lower coronary artery disease risk than women beginning treatment 10 years 
after menopause.
The  earlier  Heart  and  Estrogen  Progestin  Replacement  Study  (HERS) was  the  first 
secondary  prevention  clinical  trial  of  hormonal  therapy  that  also  did  not  demonstrate 
cardiovascular benefit. These postmenopausal women had a evidence for coronary artery disease 
(myocardial  infarction,  coronary artery bypass  grafting,  percutaneous  transluminal  coronary 
angioplasty  for  occlusion  >50  percent,  or  angiography  with  more  than  one  major  coronary 
artery).Not  only was there no overall reduction in the group receiving hormonal therapy. Also 
remarkable in HERS was the lack of secondary prevention reported in these women with known 
heart disease.
National  guidelines  have  reflected  WHI  and  HERS  results  and  emphasize  other 
modalities  for  prevention  of  heart  disease  in  women.  In  counseling  menopausal  women, 
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cardiovascular  prevention  should  be  a  focus.  Hormonal  therapy  is  used  to  control  severe 
vasomotor symptoms.
PSYCHOSOCIAL RISK FACTORS:
Both  socioeconomic  and  psychological  factors  affect  the  prevalence  and  outcome  of 
coronary artery disease. Coronary disease morbidity and mortality are greater among those of 
lower socioeconomic status (SES). Markers for SES have included years of formal education, 
owing  a  car,  income defined  by absolute  or  relative  amount,  sex,  parental  status  and  more 
recently race and ethnicity independent of other issues.
Depression is diagnosed twice as often in women as in men and affects  outcomes in 
coronary  artery  disease.  Depressive  symptoms  were  common  within  the  prior  week  in  the 
observational arm of the WHI study, which did not include participants with major depression. 
History of coronary artery disease symptoms and diagnosis increased the risk of   depression to a 
great degree than a history of a cancer.   For women without coronary artery disease history 
followed for over 4 years, depressive symptoms adjusted for age and race was independently 
associated with 58 percent higher coronary artery disease mortality.
Depressive  symptoms  screened  for  at  hospitalization  in  the  Prospective  Registry 
Evaluation Outcomes After Myocardial Infarction: Events and Recovery (PREMIER) study were 
common  and  in  this  cohort  the  depressed  young  women  had  more  co  morbidity  and  less 
favorable health and socioeconomic status. Only 18 percent of those depressed were discharged 
with  anti  depressant  medication.  Although an  adequate  pharmacologic  interventional  trial  of 
depression diagnosed after MI in women has not been reported,  selective serotonin reuptake 
inhibitors have been found to be clinically safe in the presence of cardiac disease.
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Emotional stress,  besides depression,  has also been related to  coronary artery disease 
outcomes in women. Acute and reversible cardiomyopathy has been documented after profound 
stress (28). In the Nurses’ Health study, phobic anxiety has been associated with increased risk of 
sudden cardiac death.
Acute and reversible severe cardiomyopathy was first described in Japan as tako-tsubo 
and more recently in a  series of 22 women in the United States.  The characteristics are the 
development  of  acute  symptoms  including  substernal  chest  pain  most  often  associated  with 
dependent  ST-segment  elevation  of  T  wave  inversion  of  dyspnea,  with  profound  systolic 
dysfunction and absence of significant luminal narrowing at angiography. Severe left ventricular 
systolic dysfunction and wall-motion abnormalities described as a ballooning appearance of the 
mid- and apical left ventricular base were documented and resolved over as little as 5 days or as 
long as over 2 months.
TOBACCO:
 Tobacco exposure is one of the most important coronary artery disease risk factor for 
women and men. In epidemiologic studies greater tobacco exposure in amount and duration is 
related to higher coronary artery disease events in a dose-related fashion. Cigarette smoking has 
been associated with an earlier age of first MI and menopause. Because middle-aged women 
experience less symptomatic coronary artery disease than middle-aged men, the increased risk of 
MI and sudden death related to tobacco use is greater for women than men.
Women contemplating  smoking  cessation  are  often  concerned  about  potential  weight 
gain, a common sequence of efforts to stop smoking. Weight gain with tobacco cessation is on 
average 7 to 10 pounds, with fewer than 10 percent gaining >20 pounds. Weight gain tends to be 
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higher among women, blacks, and smokers who inhale >25 cigarettes per day. To avoid weight 
gain with tobacco cessation, several types of interventions have been recommended. Realistic 
expectations  may be  helpful  as  well  as  exercise,  careful  choice  of  snacks,  and  appropriate 
pharmacotherapy. Increasing physical activity contributes to success in smoking cessation,  as 
does an increased expenditure of calories, even if it does not modify weight gain.
Multiple  pharmacologic  therapies  are  available.  Success  with  nicotine  replacement 
products is  approximately double tobacco cessation compared with tobacco cessation groups 
alone. The patch has the highest compliance rate and provides smoother levels than the gum, 
spray, or lozenge. Bupropion has been found to be effective in improving tobacco cessation rates 
in  both white  and black smokers  and is  reported to  minimize  weight  gain  while  it  is  used.  
Although bupropion is an antidepressant, it has been effective in smokers who are not depressed. 
Bupropion  is  contraindicated  in  patients  with  a  history  of  seizures,  head  trauma  and  heavy 
alcohol consumption. Bupropion can exacerbate symptoms related to anorexia and bulimia and 
should be avoided if there is history of these disorders or recent use of a monoamine oxidase 
inhibitor.
Many surveys reveal the physicians can have a powerful effect on smoking cessation, 
even with minimal effort. Programs that promote activities to minimize weight gain and stress, 
social support may be more effective for women.
RACE, WOMEN AND CORONARY ARTERY DISEASE:
Racial differences in mortality, risk factors, physiology have also begun to be considered. 
Black women’s coronary artery disease mortality rates are related to traditional coronary artery 
disease risk factors as well as racial and socioeconomic issues. 
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Combined analysis of data from the 1986 National Mortality Feedback Survey, the 1985 
National Health Interview Survey, and the U.S .Bureau of the Census revealed that black women 
younger than age 55 years had more than twice the rate of coronary artery disease mortality as 
young white Americans.Coronary artery disease death rates for young black women in this study 
exceeds rates for young men and white women. In HERS, a large secondary prevention trial of 
estrogen and progestin, black women were at increased risk for coronary events at 6 years of 
follow up.
With the application of careful methodology, Mexican American women have coronary 
artery disease mortality rates higher or equal to those of non-Hispanic white American women. 
There  are  less  data  available  on  Asian  Indian  immigrants  and  those  living  in  India,  but 
preliminary publications report high coronary artery disease rates at a young age in both men and 
women. 
SIGNIFICANT COMORBIDITIES:
 The potential relationship between medical illness associated with inflammation and the 
development of coronary artery disease has been highlighted because there has been increasing 
attention to the potential role of inflammation as an etiology of coronary artery disease. 
A case-control evaluation using population based data from  the united kingdom-based 
general  practice  research database compared 8688 patients  with  mi  with  matched controls. 
Higher  risk  of  myocardial  infarction  was  seen  in  systemic  lupus  erythematosus(SLE)  and 
rheumatoid arthritis (RA).
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SLE (systemic lupus erythematosus): 
The risk of myocardial infarction in systemic lupus erythematosus (SLE) is known to be 
increased  at  least  fivefold.  Coronary  risk  has  been  assessed  by  screening  systemic  lupus 
erythematosus  (SLE)  patients  with  electron-beam  cardiac-beam  CT and  carotid  ultrasound. 
When carotid ultrasound was completed on 197 systemic lupus erythematosus (SLE) patients 
and matched controls, carotid plaques were present among 37.1 percent of those with systemic 
lupus  erythematosus  (SLE)  compared  with  hypertensive  controls.  SLE patients  with  carotid 
plaques were generally older than age 40, with a longer duration of SLE and less likely to be 
treated with prednisone, cyclophosphamide or hydroxychloroquine.
Rheumatoid arthritis:
Rheumatoid arthritis has also been associated with increased cardio vascular mortality 
and morbidity. Coronary artery disease may occur a decade earlier. Assessment for preclinical 
evidence  of  atherosclerosis  among  98  women  with  rheumatoid  arthritis  through  carotid 
ultrasonography documented carotid  atherosclerosis  in  44 percent  of  those with  rheumatoid 
arthritis  compared to  15 percent  of  age matched hypertensive  controls.  Methotrexate,  which 
decreases the inflammatory process in rheumatoid arthritis, is also associated with lower rates of 
coronary artery disease.
INTERVENTIONS FOR CORONARY ARTERY DISEASE:
Gender  differences  in  the  prevalence  and  complication  of  percutaneous  coronary 
interventions (PCI) and CABG (coronary artery bypass grafting) surgery are evolving. There is 
controversy whether women are undertreated or men are over treated.
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Currently  approximately  33  percent  of  the  PCIs  (Percutaneous  Coronary  Interventions)  are 
performed in women. Primary angiography is superior to fibrinolytic therapy when available 
within 3 hours of symptoms, even with the higher procedure complication rate for women. The 
development of smaller coronary artery catheters only partially decreased the sex difference in 
complications.  Most  experts  note  that  the  higher  short  and  long-term complication  rates  in 
women are  probably also related  to  older  age,  more  co  morbidities,  and longer  duration  of 
symptoms  compared  to  men.  Vascular  complications  at  the  access  site,  retroperitoneal  or 
requiring transfusion are more common in women than men (29). 
 In a clinical trial comparing PCI balloon versus stenting with or without the addition of  
abciximab, overall women received treatment after a longer delay and a higher 1-year mortality, 
revascularization, and adverse cardiac events. Women benefitted most from stenting with lower 
revascularization and adverse events. In women, less vascularization in the first 30 days was 
required without an increased bleeding risk with the addition of abciximab, but no difference was 
found at  1  year.  CABG (Coronary Artery Bypass  Grafting)  surgery is  also more commonly 
performed in men than women (29).
Experience over a decade with off-pump CABG revealed women were older and had a 
smaller surface area. After controlling for these differences and other co morbidities, women had 
more wound infections and longer hospitalization but similar mortality. 
Among patients at least 75 years old at the time of CABG in the Society of Thoracic  
Surgeons’ voluntary data base, women were 38.9 percent of the sample and were older with 
smaller body surface area. Women were more likely to have emergency surgery and had higher 
operative mortality, more pulmonary and vascular complications, and longer hospitalizations (30).
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SUDDEN DEATH:
 In the Nurses’ Health Study cohort, 636 women or 57.3 percent of the cohort died out of 
the hospital or in the emergency room. There was no prior history of coronary artery disease in 
69 percent of the women with sudden death. At least one coronary risk factor was present in 94 
percent of those who died. The strongest associations were with cigarette smoking, diabetes, and 
hypertension (31). 
The Nurses’ Health Study assessed phobic anxiety, which is more common in women 
than  men,  and  found  it  correlated  with  higher  smoking  rates,  hypertension,  diabetes, 
hypercholesteremia, and BMI >30kg/m2. Similar to prior results in men, high levels of phobic 
anxiety  in  women  were  associated  with  an  increased  risk  of  fatal  coronary  artery  disease 
including  sudden  death,  even  after  controlling  for  these  co  morbidities  in  women  with  no 
coronary artery disease initially. Out-of-hospital arrest survival is similar for women and men; 
however men had higher rates of ventricular fibrillation.
ARRHYYTHMIAS:
Women generally have higher  heart  rate  than men and respond to increasing  cardiac 
demand by increasing heart rate rather than increasing stroke volume(26). Women in their seventh 
decade with a heart rate >77 beats/min had substantially higher cardio vascular and all-cause 
mortality rates than women with slower pulses with 6 years of follow up after controlling for 
potential confounders such as prior coronary artery disease, smoking, hypertension, activity level 
and anemia.
Gender differences in the incidence and management of arrhythmias have been noted. 
There is a female predominance of atrio ventricular node reentrant tachycardia and orthodromic 
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supraventricular  tachycardia,  but  men  are  likely  to  have  atrial  and  ventricular  fibrillation 
associated with wolff-parkinson-white syndrome. Although in the treatment of supra ventricular 
reentrant tachycardias there has been increasing use of radiofrequency catheter ablation therapy, 
limited data has focused on gender differences.
Overall, women have a higher risk of dying of atrial fibrillation. In an important clinical 
randomized control trial comparing rate and rhythm control in patients with atrial fibrillation 
despite prior electrical cardioversion, the primary endpoints (composite of death from coronary 
artery disease, heart failure, thromboembolism complications, bleeding, the need for pacemaker 
implantation or severe adverse effects of antiarrhythmic agents) had important sex differences.
 For  women,  rhythm  control  had  substantially  worse  outcomes  with  an  absolute 
differences of 21.5 compared with results for men revealing only a trend with absolute difference 
of 3.9. Therefore for women, it may be beneficial to focus on rate rather than rhythm control in  
persistent atrial fibrillation. 
Drug-induced torsade de pointes occurs more commonly in women than men (8).  As this 
sex difference is noticed after puberty, a prospective study explored the impact of the menstrual 
cycle on the development of torsade de pointes. After infusion of low dose ibutilide, the greatest 
increase in QT interval was seen in women during menses and in their ovulatory phase compared 
with women during luteal phase of menstruation and men.
DIAGNOSIS OF CORONARY ARTERY DISEASE IN WOMEN:
 Once coronary artery disease is considered as a diagnosis, further evaluation is required 
to assess disease presence and severity. Exercise stress testing was the earliest noninvasive way 
to assess coronary artery disease risk. However, women have lower sensitivity and specificity 
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with exercise stress testing than men, in part related to lower ecg voltage. In multiple populations 
women have been noted to have more frequent ST-T-wave changes (32). Gender-specific criteria 
for exercise stress testing interpretation have been proposed to compensate for generally smaller 
ST-segment changes seen in women.
After exercise stress testing, the maximal exercise capacity and heart rate recovery in 
women  are  important  prognostically.  Among  asymptomatic  women  with  low  Framingham 
scores, those with lower exercise capacity and slower heart rate recovery were at increased risk 
for CV death. 
Stress  imaging  techniques  are  often  required  in  assessing  symptomatic  women  for 
severity of coronary artery disease. Nuclear stress perfusion testing in women can be potentially 
hindered by soft tissue attenuation from breast tissue with the use of thallium, so technetium may 
be preferred.  Stress echocardiography is  highly dependent  on operator  expertise  and may be 
technically difficult in obese patients.
Because cardiac catheterization is less likely to reveal coronary artery disease in women, 
many clinicians initially evaluate women at intermediate risk with stress-imaging techniques. For 
example, anginal symptoms are less predictive of abnormal coronary anatomy in women than 
men. Direct referral to cardiac catheterization should occur with a high suspicion of significant 
coronary artery disease that might benefit from intervention or after an abnormal noninvasive 
stress test.
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ST  Elevation  Myocardial  Infarction  (STEMI)  -  Pathology,  clinical  features  and 
management:
The classic World Health Organization (WHO) criteria for the diagnosis of MI require 
that at least two of the following three elements be present: a history of ischemic-type chest 
discomfort, evolutionary changes on serially obtained ECG tracings, and a rise and fall in serum 
cardiac markers (33).
Revised Definition of Myocardial Infarction (MI) (34)
 A. Criteria for Acute, Evolving, or Recent MI:
1. Typical rise and/or fall of biochemical markers of myocardial necrosis with at least one of the 
following
A)    Ischemic symptoms 
B)    Development of pathological Q waves in the ECG 
C)    ECG changes indicative of ischemia (ST segment elevation or depression) 
D)    Imaging evidence of new loss of viable myocardium or new regional wall 
motion abnormality 
2. Pathological findings of an acute myocardial infarction.
(Either of the above criteria satisfies the diagnosis for acute, evolving or recent MI)
B. Criteria for Healing or Healed Myocardial Infarction:
1.  Development  of  new pathological  Q waves  in  serial  ECGs.  The patient  may or  may not 
remember  previous  symptoms.  Biochemical  markers  of  myocardial  necrosis  may  have 
normalized depending on the length of time that has passed since the infarction developed.
2. Pathological findings of a healed or healing infarction.
(Any one of the above criteria satisfies the diagnosis for healing or healed MI)
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Pathology :
Almost  all  myocardial  infarctions result  from coronary atherosclerosis,  generally with 
superimposed coronary thrombosis.
Plaque :  
During the natural evolution of atherosclerotic plaque, especially that which is lipid laden, 
an  abrupt  and  catastrophic  transition  can  occur,  characterized  by  plaque  disruption.  Some 
patients have a systemic predisposition to plaque disruption that is independent of traditional 
risk factors. 
Plaque disruption exposes substances that promote platelet activation and aggregation, 
thrombin generation, and ultimately thrombus formation  (35).] The resultant thrombus interrupts 
blood  flow  and  leads  to  an  imbalance  between  oxygen  supply  and  demand  and,  if  this 
imbalance is severe and persistent, to myocardial necrosis .
Composition of plaques :
At autopsy, the atherosclerotic plaques of patients who died of STEMI are composed 
primarily  of  fibrous  tissue  of  varying  density  and  cellularity  with  superimposed  thrombus. 
Calcium, lipid-laden foam cells, and extracellular lipid each constitute 5 to 10 percent of the 
remaining  area.  Coronary arterial  thrombi  responsible  for  STEMI  are  approximately  1cm in 
length in most cases; adhere to the luminal surface of an artery; and contain platelets, fibrin, 
erythrocytes, and leukocyte. The composition of the thrombus may vary at different levels: A 
white thrombus is composed of platelets, fibrin, or both, and a red thrombus is composed of 
erythrocytes, fibrin, platelets, and leukocytes. Early thrombi are usually small and nonocclusive 
and are composed predominantly of platelets. 
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Causes of Myocardial Infarction without Coronary Atherosclerosis (36) :
1. Coronary artery disease Other than Atherosclerosis
     -Arteritis
Luetic
Granulomatous (Takayasu disease)
Polyarteritis nodosa 
Mucocutaneous lymph node (Kawasaki) syndrome
    -Trauma to coronary arteries 
    -Coronary mural thickening with metabolic disease or intimal proliferative disease (Hurler, 
Fabry disease, Homocystinuria, Amyloidosis)
2. Emboli to Coronary Arteries
3. Congenital Coronary Artery Anomalies
4. Miscellaneous (cocaine abuse, myocardial contusion, Polycythemia vera )
Risk Factors for Atherothrombotic Diseases in Women:
Smoking
Hypertension
Hyperlipidemia and Elevated Low-Density Lipoprotein Cholesterol
The metabolic syndrome
Insulin resistance
Obesity
Diabetes
Polycystic ovary disease
Age >55yr
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Inactivity
Homocysteine elevations
Family history of premature coronary death: younger than 55 yr in men and  
65 yr in women (first degree relative)
Lipoprotein(a)
Oral contraceptive use in the presence of other risk factors
CLINICAL FEATURES:
1. Chest pain : 
The pain of STEMI varies in intensity; in most patients, it is severe and in some instances 
intolerable. The pain is prolonged, usually lasting for more than 30 minutes and frequently for a 
number of hours. 
 The discomfort is described as constricting, crushing, oppressing, or compressing; often 
the patient complains of a sensation of a heavy weight or a squeezing in the chest. Although the 
discomfort  is  typically  described  as  a  choking,  viselike,  or  heavy  pain,  it  can  also  be 
characterized  as  a  stabbing,  knifelike,  boring,  or  burning  discomfort.  The  pain  is  usually 
retrosternal in location, spreading frequently to both sides of the anterior chest, with predilection 
for the left side.
2. OTHER SYMPTOMS: 
Nausea and vomiting may occur, presumably because of activation of the vagal reflex or 
stimulation of left ventricular receptors as part of the Bezold-Jarisch reflex. These symptoms 
occur  more  commonly in  patients  with  inferior  STEMI than in  those  with anterior  STEMI. 
Moreover, nausea and vomiting are common side effects of opiates. 
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When the pain of STEMI is  epigastric  in  location and is  associated with nausea and 
vomiting, the clinical picture can easily be confused with that of acute cholecystitis, gastritis, or 
peptic ulcer. Occasionally, a patient complains of diarrhea or a violent urge to defecate during the 
acute  phase  of  STEMI.  Other  symptoms  include  feelings  of  profound  weakness,  dizziness, 
palpitations, cold perspiration, and a sense of impending doom.
3. SILENT STEMI: 
Unrecognized or silent infarction occurs more commonly in patients without antecedent 
angina  pectoris  and  in  patients  with  diabetes  and  hypertension  (37).  Silent  STEMI  is  often 
followed by silent ischemia. The prognoses of patients with silent and symptomatic presentations 
of STEMI appear quite similar.
        4. Atypical presentations of STEMI:
 (1) Heart failure (i.e.,  dyspnea without pain beginning de novo or worsening of established 
failure); 
(2) Classic angina pectoris without a particularly severe or prolonged episode;
 (3) Atypical location of the pain;
 (4) Central nervous system manifestations, resembling those of stroke, secondary to a sharp 
reduction  in  cardiac  output  in  a  patient  with  cerebral  arteriosclerosis;  (5)  apprehension  and 
nervousness; 
(6) Sudden mania or psychosis; 
(7) Syncope;
 (8) Overwhelming weakness; 
(9) Acute indigestion;
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 (10) Peripheral embolization.
Laboratory findings: 
1. Serum Markers of Cardiac Damage : 
i. CREATINE KINASE(CK) : 
Serum CK activity exceeds the normal range within 4 to 8 hours after the onset of STEMI 
and declines to normal within 2 to 3 days. Although the peak CK occurs on average at about 24 
hours,  peak  levels  occur  earlier  in  patients  who  have  had  reperfusion  as  a  result  of  the 
administration of fibrinolytic therapy or mechanical recanalization (as well as in patients with 
early spontaneous fibrinolysis). Because reperfusion influences the time-activity curve of serum 
CK, and because reperfusion itself influences infarct size, reperfusion confounds estimation of 
infarct size by enzyme analysis (38).
ii. CREATINE KINASE ISOENZYMES:  
Creatine kinase MB is analyzed in most laboratories by highly sensitive and specific 
enzyme immunoassays that  utilize monoclonal antibodies directed against  CK-MB  (39).  Mass 
assays report results in nanograms per milliliter rather than units per milliliter and have been 
confirmed to be more accurate than CK-MB activity assays, especially in patients presenting 
within 4 hours of the onset of STEMI. 
It has been proposed that a ratio (relative index) of CK-MB mass to CK activity of about 
2.5 is indicative of a myocardial rather than a skeletal source of the CK-MB elevation.
 Although this ratio may be satisfied by many patients with STEMI, it is inaccurate in 
several circumstances: (1) when high levels of total CK are present because of skeletal muscle 
injury (a large quantity of CK-MB must be released from the myocardium to satisfy criteria); (2)  
when chronic skeletal muscle injury releases large amounts of CK-MB; and (3) when total CK 
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measurements are within the normal reference range for the laboratory and CK-MB is elevated 
(possibly indicating that a microinfarction has occurred). Patients with minimally elevated CK-
MB  and  normal  CK  have  a  prognosis  that  is  generally  worse  than  that  for  patients  with 
suspected MI but no CK-MB elevation.
iii. CARDIAC-SPECIFIC TROPONINS: 
Although both TnT and TnI are present in cardiac and skeletal muscle, they are encoded 
by  different  genes  and  their  amino  acid  sequence  differs.  This  permits  the  production  of 
antibodies that are specific for the cardiac form (cTnT and cTnI) and has led to the development 
of  quantitative  assays for  cTnT and cTnI  that  have been approved by the Food and Drug 
Administration for clinical use. 
Several  studies  have  confirmed  the  reliability  of  these  new  quantitative  assays  for 
detecting myocardial injury, and measurement of cTnT or cTnI is now at the center of the new 
diagnostic criteria for MI.
 In patients with MI, cTnT and cTnI first begin to rise above the upper reference limit by 3 
hours from the onset  of  chest  pain.  Because of  a continuous release from a degenerating 
contractile apparatus in necrotic myocytes, elevations of cTnI may persist for 7 to 10 days after 
MI;  elevations of  cTnT may persist  for  up to 10 to 14 days.  The prolonged time course of 
elevation of cTnT and cTnI is advantageous for the late diagnosis of MI. Patients with STEMI 
who  undergo successful  recanalization  of  the  infarct-related artery have a  rapid  release  of 
cardiac troponins that also may be useful as an indicator of reperfusion.
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Troponin Versus CK-MB: 
When comparing the diagnostic efficiency of the cardiac troponins versus CK-MB for 
MI, it  is  important to bear in mind that the troponin assays  can probably detect episodes of 
myocardial necrosis that are below the detection limit of the current CK-MB assays, leading to a 
number  of  “false-positive”  cases  of  troponin  elevations  if  CK-MB is  used  as  the  reference 
standard  or,  conversely,  false-negative  cases  of  CK-MB elevation  if  troponin  is  used as  the 
reference standard.
RECOMMENDATIONS FOR MEASUREMENT OF SERUM MARKERS:  
  It seems reasonable for clinicians to measure either cTnT or cTnI in all patients with 
suspected MI.  From a  cost-effectiveness  perspective,  it  is  unnecessary to  measure both  a 
cardiac-specific troponin and CK-MB. Routine diagnosis of MI can be accomplished within 12 
hours using CK-MB, cTnT, or cTnI by obtaining measurements approximately every 8 to 12 
hours. 
Retrospective diagnosis or diagnosis of MI in the presence of skeletal muscle injury is 
more  readily  accomplished  with  cTnT or  cTnI.  With  increasing  familiarity  of  clinicians  with 
assays for the cardiac-specific troponins, it is anticipated that they will supersede assays for CK-
MB not only for the diagnosis of MI but also for assessment of reperfusion, reinfarction, and 
estimation of infarct size (40).
MYOGLOBIN:
Peak levels of serum myoglobin are reached considerably earlier (1 to 4 hours) than 
peak values of serum CK. Because of its lack of cardiac specificity, an isolated measurement of 
myoglobin within the first  4 to 8 hours after the onset of chest discomfort in patients with a 
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nondiagnostic  ECG  should  not  be  relied  on  to  make  the  diagnosis  of  MI  but  should  be 
supplemented by a more cardiac-specific marker such as cTnI or cTnT.
SERUM LIPIDS:
 During  the  first  24  to  48  hours  after  admission,  total  cholesterol  and  high-density 
lipoprotein (HDL) cholesterol remain at or near baseline values but generally fall precipitously 
after that. The fall in HDL cholesterol after STEMI is greater than the fall in total cholesterol; thus 
the ratio of total cholesterol to HDL cholesterol is no longer useful for risk assessment unless 
measured early after  MI.  A lipid  profile  should  be obtained on all  STEMI  patients  who are 
admitted within 24 to 48 hours of symptoms.
HEMATOLOGICAL FINDINGS: 
The elevation of the white blood cell  count usually develops within 2 hours after the 
onset of chest pain, reaches a peak 2 to 4 days after infarction, and returns to normal in 1 week; 
the peak white blood cell count usually ranges between 12  and 15× 103/ml but occasionally 
rises to as high as 20× 103/ml in patients with large STEMI.
The erythrocyte sedimentation rate (ESR) is usually normal during the first day or two 
after infarction, even though fever and leukocytosis may be present. It then rises to a peak on 
the fourth or fifth day and may remain elevated for several weeks. The increase in the ESR 
does not correlate well with the size of the infarction or with the prognosis.
The hemoglobin value at presentation with STEMI powerfully and independently predicts 
major cardiovascular events (41).
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Electrocardiography (ECG):
 Although general  agreement  exists  on electrocardiographic  and vectorcardiographic 
criteria  for  the  recognition  of  infarction  of  the  anterior  and  inferior  myocardial  walls,  less 
agreement pertains to criteria for lateral and posterior infarcts; in this area, even the terminology 
can be confusing. A consensus group has recommended elimination of the term “posterior” and 
suggests using “lateral” to be consistent with current understanding of the segmental anatomy 
of the heart as it sits in the thorax.
 Patients with an abnormal R wave in V1 (0.04 second in duration and/or R/S ratio ≥1 in 
the absence of preexcitation or right ventricular hypertrophy) with inferior or lateral Q waves 
have an increased incidence of isolated occlusion of a dominant left circumflex coronary artery 
without collateral circulation; such patients have a lower ejection fraction, increased end-systolic 
volume, and higher complication rate than patients with inferior infarction because of isolated 
occlusion of the right coronary artery.
Q-WAVE AND NON-Q-WAVE INFARCTION:
 As noted earlier, the presence or absence of Q waves on the surface ECG does not 
reliably distinguish between transmural and nontransmural (subendocardial) MI (42). Q waves on 
the ECG signify abnormal electrical activity but are not synonymous with irreversible myocardial 
damage. Also, the absence of Q waves may simply reflect the insensitivity of the standard 12-
lead ECG, especially in zones of the left ventricle supplied by the left circumflex artery . 
Angiographic  studies  in  MI  patients  without  ST-segment  elevation  show  a  higher 
incidence of subtotal occlusion of the culprit coronary vessel and greater collateral flow to the 
infarct  zone.  Observational data suggest that MI without ST-segment elevation occurs more 
commonly in elderly patients and patients with a prior MI.
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Chest roentgenogram :
 The degree of congestion and the size of the left side of the heart on the chest film are 
useful for defining groups of patients with STEMI who are at increased risk of dying after the 
acute event.
Echocardiography: 
The relative portability of echocardiographic equipment makes this technique ideal for 
the  assessment  of  patients  with  MI  hospitalized  in  the  coronary  care  unit  or  even  in  the 
emergency department before admission.
 In patients with chest pain compatible with MI but with a nondiagnostic ECG, the finding 
on echocardiography of a distinct region of disordered contraction can be helpful diagnostically 
because it supports the diagnosis of myocardial ischemia.
Areas of abnormal regional wall motion are observed almost universally in patients with 
MI, and the degree of wall motion abnormality can be categorized with a semiquantitative wall  
motion score index. Of note, abnormal wall motion is less often noted echocardiographically 
when the infarction is small and the age of regional wall motion abnormality cannot always be 
determined.
 Left ventricular function estimated from two-dimensional echocardiograms correlates 
well with measurements from angiography and is useful in establishing prognosis after MI (43). 
Furthermore, the early use of echocardiography can aid in the early detection of potentially 
viable but stunned myocardium (contractile reserve), residual provocable ischemia, patients at 
risk for the development of congestive heart failure after MI, and mechanical complications of 
MI.Management:
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i. Management in the Emergency Department:  the goals are 
    - Control of cardiac discomfort
        - Rapid identification of patients who are candidates for reperfusion therapy
        - Triage of lower-risk patients to appropriate location in the hospital
         -Avoidance of inappropriate discharge of patients with STEMI
        -Aspirin (160 mg-325 mg)
        -Nasal O2 if when hypoxemia is present
ii. Control of Discomfort:
i.Sublingual nitroglycerin : 
Up to three doses of 0.4 mg should be administered at about 5-min intervals. By virtue of 
their ability to enhance coronary blood flow by coronary vasodilation and to decrease ventricular 
preload by increasing venous capacitance, sublingual nitrates are indicated for most patients 
with an acute coronary syndrome. At present, the only groups of patients with STEMI in whom 
sublingual nitroglycerin should not be given are those with inferior MI and suspected right 
ventricular infarction or marked hypotension (systolic pressure <90 mm Hg), especially if 
accompanied by bradycardia.
Intravenous Morphine of 2-4mg: 
The reduction of anxiety resulting from morphine diminishes the patient's restlessness 
and the activity of the autonomic nervous system, with a consequent reduction of the heart's 
metabolic  demands.  The beneficial  effect  of  morphine in  patients  with pulmonary edema is 
unequivocal  and may be related to  several  factors  including peripheral  arterial  and venous 
dilation (particularly among patients with excessive sympathoadrenal activity), reduction of the 
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work of breathing, and slowing of heart rate secondary to combined withdrawal of sympathetic 
tone and augmentation of vagal tone.
Intravenous beta blockers: 
These drugs relieve pain,  reduce the need for  analgesics in  many patients,  and reduce 
infarct  size and life-threatening arrhythmias.  Avoiding early intravenous blockade in patients 
presenting in Killip Class II or greater is important, however, because of the risk of precipitating 
cardiogenic shock. 
A popular and relatively safe protocol for the use of a beta blocker in this situation is as 
follows
. (1) Patients with heart failure (rales >10 cm up from diaphragm), hypotension (blood 
pressure <90 mm Hg), bradycardia (heart rate <60 beats/min), or heart block (PR interval 
>0.24 sec) are first excluded.
 (2) Metoprolol is given in three 5-mg intravenous boluses. 
(3) Patients are observed for 2 to 5 minutes after each bolus, and if the heart rate falls 
below 60 beats/min or systolic blood pressure falls below 100 mm Hg, no further drug is 
given.
Management: 
The primary tool for screening patients and making triage decision is the initial 12-lead 
ECG. When ST-segment elevation of at least 2mm in two contagious precordial leads and 1mm 
in  two  contagious  limb  lead  is  present  ,  a  patient  should  be  considered  a  candidate  for 
reperfusion therapy.
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The process of selecting patients for fibrinolysis versus PCI ( percutaneous coronary 
intervention) is discussed below. In the absence of ST-segment elevation,  fibrinolysis is not 
helpful, and evidence exists suggesting that it may be harmful.
Reperfusion Options for STEMI Patients (44):
Step 1: Assess time and risk:
- Time since onset of symptoms
- Risk of STEMI
- Risk of fibrinolysis
- Time required for transport to a skilled PCI laboratory
Step 2: Determine if . brinolysis or invasive strategy is preferred
- If  presentation is <3 hr and there is no delay to an invasive strateg y,  there is no 
preference for either strategy.
Fibrinolysis is generally preferred if:
i. Early presentation (≤3 hr from symptom onset and delay to invasive strategy) 
ii. Invasive strategy is not an option:
- Catheterization laboratory occupied or not available
-Vascular access difficulties 
- Lack of access to a skilled PCI laboratory
- Delay to invasive strategy (delay in transport)
 An invasive strategy is generally preferred if (44):
- Skilled PCI lab is available with surgical backup
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-High risk from STEMI 
- Cardiogenic shock
- Killip class ≥3
- Contraindications to fibrinolysis including increased risk of bleeding, ICH
-Late presentation 
- Symptom onset was more than 3 hr ago
-Diagnosis of STEMI is in doubt.
Contraindications and Cautions for Fibrinolytic Use in STEMI (44):
Absolute Contraindications:
- Any prior intracranial hemorrhage 
- Known structural cerebral vascular lesion (e.g., arteriovenous malformation) 
- Known malignant intracranial neoplasm (primary or metastatic) 
- Ischemic stroke within 3 mon except acute ischemic stroke within 3 hr 
- Suspected aortic dissection 
- Active bleeding or bleeding diathesis (excluding menses) 
- Significant closed head or facial trauma within 3 mo 
Relative contraindications:
- Severe uncontrolled hypertension on presentation (SBP >180 Hg or DBP >110 Hg)
- History of prior ischemic stroke >3 mo dementia,  or known intracranial  pathology not 
covered in contraindications
- Traumatic or prolonged (>10 min) CPR or major surgery (<3 wk)
- Recent (within 2-4 wk) internal bleeding
- For streptokinase/anistreplase: prior exposure (>5 days ago) or prior
- Pregnancy
- Active peptic ulcer
- Current use of anticoagulants: the higher the INR, the higher the risk of bleeding
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MATERIALS AND METHODS
    The  study  was  conducted  at  intensive  cardiac  care  unit  of  Govt.  Stanley  Hospital, 
Chennai during July 09 to November 09.
• This study was done as a descriptive study.
• Ninety  female  patients  admitted  with  clinical  features  and  ECG  changes 
suggestive of ST segment elevation myocardial infarction, elevated CK-MB taken 
as cases.
• Inclusion criteria:
                      - Female patients admitted with the clinical features and ECG changes  
suggestive of STEMI.
•   Exclusion criteria: 
- Female patients with unstable angina, NSTEMI (Non STEMI)
-Female patients with ST elevation without both symptoms and enzyme elevation.
• Ninety  patients  were  examined  and  detailed  history  with  regard  to 
history risk factor analysis was made. 
• Baseline  investigations  like  complete  blood  count,  renal  function  test,  Urine 
routine examination, Chest x ray and ECG were taken. 
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• In this study, clinical symptoms like chest pain and association with sweating, 
palpitation, nausea, vomiting and breathlessness were all taken into account and 
percentage of each was studied.
• Physical signs like hypertension, hypotension, raised JVP, S3, S4, crackles and 
wheeze were all looked for.
• Hypertension  was  considered  by  documentary  history  of  hypertension  on 
medication or BP >140/90 mmHg.
• Diabetes mellitus was considered either by documentary history of treatment or 
fasting blood sugar >126mg/dl and postprandial blood sugar >200mg/dl.
• Serum cholesterol was done for all patients and lipid profile was also done.
LDL, HDL and triglycerides levels were taken into the study.HDL level was graded as 
>50mg/dl,  40-50mg/dl  ,40-30mg/dl,30-20mg/dl  and  <20mg/dl.LDL levels  should  be 
ideally <130 mg/dl and LDL level was graded as >130mg/dl,130-160mg/dl and >160 
mg/dl.
• Patients were grouped into four categorized according to their age as <45yrs,45 
-60 yrs, 60-75yrs  and >75 yrs.
• A detailed family history,  socioeconomic  status,  occupation,  menstrual  history, 
diet and lifestyle were obtained.
• Killip   score  is  calculated  based  on  classification  according  to  the  status  of 
cardiac pump function , estimated clinically
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Class I –    No signs of pulmonary congestion or shock 
Class II –   Moderate heart failure as evident by rales at the lung bases, S3  
gallop, tachypnoea  
Class III-   Severe heart failure (pulmonary edema)
Class IV-   Cardiogenic shock with systolic BP < 90 mmHg, peripheral       
Vasoconstriction, cyanosis, oliguria and confusion 
• Body Mass Index (BMI) was calculated by using Weight in kilogram/height2 in 
metre2.
• Type of myocardial infarction was based on surface ECG       
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Type of Myocardial Infarction(MI) ECG pattern
Anterior wall MI(extensive)(AWMI) Typical infarction pattern in lead I,aVL,V1-V6
Antero septal MI(ASMI) Infarction pattern in lead V1-V4
Lateral Wall(Apical) MI(LWMI) Infarction pattern in lead V5,V6
Anterolateral wall MI Lead I,aVL,V4-V6
Inferior Wall MI(IWMI) Lead II,III,aVF
IWMI + Right Ventricular MI Lead II,III,aVF+ Righted sided lead V4R
IWMI + RWMI + Posterior Wall MI Lead  II,III,aVF  +   lead  V4R  +mirror  image 
classical pattern in V1-V3
Combined. others Depends on type of involvement 
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OBSERVATIONS
Clinical presentation-Symptoms:
• 79% (71 out of the 90 patients) of the patients with ST elevation MI had mild to severe 
chest pain. The character of the pain was assessed to be squeezing or compressing in 
nature with characteristic radiation in 27% of the 71patients.
• 21% of the patients (19 out of the 90 patients) presented only with breathlessness without 
chest pain.
• One patient presented with cerebro vascular accident(CVA)
                                         Table 1
                    Clinical presentation
    Symptoms No.  of  Cases(total 
cases=90)
Chest pain(mild to severe angina) 71
Radiation 19
Vomiting 15
Nausea 17
Breathlessness 29
Breathless without Chest pain 19
Palpitation 22
Epigastric pain 12
Others (CVA, Asymptomatic) 1
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In our study, out of 90 patients, 19 patients were presented without typical chest pain.
Table 2
Age wise distribution of patients without chest pain:
Age No. of patients
<45 yrs 0
45-60 2
60-75 7
>75yrs 10
Total 19
Age wise distribution of patients without chest pain:
Table 3
Prevalence of Diabetes in patients presented without chest pain:
Diabetic status No. of patients
Diabetic 12
Non-diabetic 7
Total 19
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CLINICAL PRESENTATION – SIGNS:
• Basal crackle is the most common presenting sign. Jugular venous pressure is elevated in 
7 patients.
• Basal crackles were found in 36% (32 out of the 90)patients.
• Three  patients  were  in  hypotension  and  six  patients  were  admitted  with  mitral 
regurgitation.
                                                      
Table 4
Signs No. of cases (total 90)
Hypertension 27
Hypotension 3
Crackles 32
Raised JVP 12
Associated MR 6
Pedal edema 18
Apical shift 13
Wheeze 7
S3 21
S4 5
Pallor 24
 Killip Classification:
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In our study, most of the patients presented with Killip Class I. Out of the 90 patients, 58 patients 
presented with Killip class I and 20 patients were in Class II.
Table 5
                         Number of patients according to Killip Classification:
          Class No of cases(Total=90)
Class I 58
Class II 20
Class III 9
Class IV 3
Thrombolysis: 
In  our  study,  48  patients  (53%) were  thrombolysed  and 42 patients  (47%) were  not 
thrombolysed
Incidence of non-thrombolysis due to various reasons increases with the age.55% 
of female with age 75 and above were not thrombolysed, compared to 40% in women in age 60 
and less than 60 yrs.
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Table 6
Age distribution Thrombolysed Not thrombolysed
Age <45yrs 2 2
Age 45-60yrs 16 10
Age 60-75 yrs 16 13
Age >75 yrs 14 17
Total 48 42
Age: 
Incidence of myocardial infarction increases with the age. In our study 67% of the patients were 
in the age of >60yrs.
50
Table 7
Age wise distribution of patients(Total-90)
Age Distribution No. of the patients
Age <45yrs 4
Age 45-60yrs 26
Age 60-75 yrs 29
Age >75 yrs 31
    
          Diabetes :
In our study, 58% population(52 out of the 90 patients)  found to have diabetes.
Table 8
Diabetic status in study population
Diabetic 52
Non Diabetic 38
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Diabetic status:
Hypertension:
In our study, 40% population (36 out of the 90 patients) found to have hypertension.
Dyslipidemia:
Total cholesterol was measured for all patients. Lipid profiles mainly LDL, HDL were 
measured. Out of the 90 patients, 81 patients were found to have dyslipidemia.
LDL Cholesterol level:
Table-9
HDL Cholesterol  level No. of Patients
<20 mg/dl 7
20-30 mg/dl 37
30-40 mg/dl 27
40-50 mg/dl 14
>50 mg/dl 5
HDL Cholesterol:
                           Table-10
LDL Cholesterol No. of patients
<130 mg/dl 16
130-160 mg/dl 23
>160 mg/dl 51
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Obesity:
Obesity is an independent risk factor for increased mortality. In our study, 59% percent 
(26 patient in  Class I  Obese,  22 in  Class II  Obese and 3 in Morbid Obese) were in  obese 
category and 29% percent(26 patient) were in overweight category.
Table -11
Classification of Overweight and Obesity by BMI for Indians:
Obesity class BMI (kg/m2) No. of patients
Underweight      <18.5 0
Normal 18.5-22.9 9
Overweight  23.0-27.9 26
Obesity Class I 28.0-32.9 29
Obesity Class II 33.0-37.9 23
Extreme Obesity Class III >38 3
Alcohol and Smoking:
Prevalence  of smoking and alcohol in our study was zero percent..
Type of Myocardial Infarction :
In our study, Anteroseptal and anterior wall myocardial infarction were the two common 
type of myocardial infarction.
                                        
53
                                                          Table-12
Type of Myocardial Infarction(MI) No. of patients
ASMI 26
AWMI 17
ALMI 10
Apical(lateral)MI 3
IWMI 19
IWMI+RVMI 11
IWMI+RVMI+PWMI 4
            Total cases = 90 and Distribution of cases depends on surface ECG:
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Discussion
Women constitute 48% of the total population in India, However, due to 
inadequate perception and attention, coronary heart disease remains a formidable health 
problem in women.
The lifetime risk of a woman dying from heart disease is more than eight-times 
than from breast cancer, yet they fear more for breast cancer and neglect any precautions 
for heart diseases. It is estimated that 31% of women will die from coronary artery 
disease; yet, about 70% of university educated women consider their risk of coronary 
artery disease to be <1%.
In our study, 71 out of the 90 patients (79%) had typical angina symptoms. The 
other two common symptoms in our study, were breathlessness and palpitation
In our study, 21% (19 out of the 90 patients) of patients were presented without 
chest pain and 18% of patients were presented with atypical symptoms like vomiting, 
nausea and epigastric pain. Out of those 19 patients, 10 patients were in the age group of 
>75 years and 12 patients were diabetic.
In a study by Marrugat et al.,( 1998) showed that women are more likely to have 
symptoms such as nausea, instead of chest pain.
In our study, 67% of patients were in the age group of above 60yrs. Coronary 
artery disease mortality among women gradually increases with age and increase in the 
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risk of coronary artery disease is related to a higher incidence of hypertension, diabetes, 
dyslipidemia, and obesity.
In our study, 58% were found to have diabetes. Cardiovascular disease is the most 
common complication of diabetes in women, and diabetes is the only condition that 
causes women to have rates of coronary artery disease similar to those of men.
Huxley and colleagues found women with diabetes had 3.5 fold increase in 
cardiovascular mortality compared with non-diabetic women as well as their male 
counterpart.
Diabetes confers substantial increased relative risk of first, incident, and admission 
for MI for women compared with age-to-sex matched controls younger than age 65 yrs 
over 20 yrs follow up in Copenhagen City Heart Study13.
In our study, 40 % were found to have hypertension. Having hypertension raises a 
woman’s risk of heart disease four fold, and her risk of dying from a coronary event 
seven-fold. Besides the usual factors-salt intake, inactivity, age, and genetics-
hypertension in women is particularly closely correlated with obesity.
In our study, prevalence of smoking and alcohol was zero percent and India is 
fortunate in that like other Asian countries only few women smoke, which is lower than 
many western countries. But even then they are not saved from the harmful effects of 
passive smoking, as their male counterparts smoke with high prevalence of 60%.
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A study by Liaquat Ali Cheema et al., (Gender comparison of coronary 
risk factors and clinical presentation in Pakistani patients with coronary artery 
lesions):
This showed that smoking was not a risk factor in females in the study 
population and diabetes mellitus was more common in females while smoking 
and dyslipidemia in males.
H Fu and Y Zhao  study: (study of risk factors for female patients with acute 
myocardial infarction,2009)
Five hundred and eighty female patients were compared with 2,058 male patients 
for age, occupation, positive family history, type 2 diabetes mellitus, hypertension, and 
hyperlipemia.
Compared with male patients, female patients with AMI were older, and type 2 
diabetes mellitus and hypertension probably played more important roles in female 
patients.
In a study by V. Chiamvimonvat and L. Sternberg(University of Toronto):
Coronary artery disease is the leading cause of mortality in women, with incidence 
after menopause equal to that of men. Diabetes and postmenopausal status without 
hormone replacement therapy are the strongest risk factors.
Women with myocardial infarction are more likely to have atypical symptoms, 
including nonexertional chest pain; pain in other locations, such as jaw, arms, shoulder, 
57
back, and epigastrium; and angina-equivalents, such as dyspnea, palpitations, and 
presyncope.
Halvorsen S and Risoe C. study: (Symptoms and diagnosis of coronary heart 
disease in women)
Myocardial infarction hits women about ten years later than men, but women with 
risk factors lose their sex advantage. Women with coronary disease are less likely to 
experience chest pain than men and may have less specific symptoms.
Mosca et al study:
In this study, compared with male patients, female patients have 41% 
identified being overweight,, 36% said smoking, 31% cited high cholesterol, 29% 
identified family history, 19% said hypertension, 19% identified diabetes and 1% 
said high triglyceride level (Mosca et al., 2004).
In our study, 29% of patients were in overweight category(BMI=>23 to <27.9) and 
61% were obese(BMI >28). Obesity is linked to multiple cardiac risk factors 
(including insulin resistance, diabetes, hypertension, and hyperlipidemia) and 
independently associated with coronary artery event rates.
In the Nurses’ Health Study, both BMI >25 and physical activity were 
important predictors of coronary artery disease in 20 years follow up.
Women with a elevated total cholesterol were approximately twice as likely to 
develop coronary artery disease as those with cholesterol levels of 205mg/dl or 
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lower. In its recent guidelines, the American Heart Association(AHA) has 
changed the cut-point for what constitutes low HDL-C in women from less than 
40 to less than 50.
In our study, 94% had low HDL-C cholesterol(<50mgt/dl). LDL-C (low 
density lipoprotein) levels increase with increasing age for both women and men 
and especially important in women.
The LDL fraction of total cholesterol is a strong predictor of coronary artery 
disease mortality in women as well as men. Unlike in men whose LDL-C levels 
plateau at the age of 50 yrs, the LDL-C levels in women increase steadily by 
average of 2 mg/dl/yr between the age of 40 to 60 (total of 40mg/dl). The 
optimum LDL-C level is <100mg/dl
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Conclusion
The following are conclusions that could be inferred from this study on clinical spectrum 
and risk factors among female patients.
• The most common symptom is chest pain.
• Atypical symptoms are more common in older females and diabetic patients.
• The most common cardiovascular sign is crackles. 
• Most of the patients belonged to Killip Class-I.
• Most common age group affected was above 60yrs and showing that risk of myocardial 
infarction increases proportionately with age.
• Diabetes is clearly related to risk of myocardial infarction.
• Both obesity and hypertension are also associated with increased risk of myocardial 
infarction in female population.
• Most of the patients with myocardial infarction have dyslipidemia.
• Most common type of myocardial infarction is anteroseptal myocardial infarction(ASMI)
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                                                       PROFORMA:
1. Name
2. Age
3. Marrital status
4. No of Children
5. Educational status
6. Occupation
7. Family Income/yr
8. Address :
9. Hgt in cms
10. Wgt in kgs
11. BMI(kg/M2)
12. Clinical presentation on admission: Chest pain / Nausea / vomiting / Epigastric pain /  Jaw 
pain / Left arm pain /  Sweating/ Dyspnoea / Palpitation / Syncope / Others
13. Time of Onset of symtoms :
14. Hypertension : Y / N
        How many yrs:
        Treatment       :
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15.Diabetes :       Y / N
        Type    :
        Treatment:
16.Hyperlipidemia :  Y/N
       Treatment:
17. Alcohol : Y /N 
18.  Smoking: Y / N
19. Family H/O of IHD: 
20. Sedentary habits:
21. Menstrual H/O:  Premenopausal / Postmenopausal
          Menopause:        Yrs since menopause
 22. Diet H /O : Veg  / Non Veg
          Frequency
          Duration
          Type of cooking oil
           Salt intake
          Coffee/Tea
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  23. General examination
              Conscious:                         Orientation
  BP:                     
  PR:    
 Anemia:                  
Cyanosis:  
Clubbing:
Icterus:                   
Pedal edema:            
Markers of Hypercholesteremia
24. CVS: 
       Apical Impulse:
       Heart sounds:
       Murmurs: 
        Rub:
25. RS :
        Air entry:
        Adventitious sounds
26. P /A:
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27. CNS:
nvestigations:
 1.Urine R /E : Albumin
                          Sugar
                         Deposits
2.RFT :Urea 
            Creatinine
            Electrolytes
3.CBC: Total Count                   Differential Count                
            Erythrocyte Sedimentation Rate
            Hemoglobin                   Platelets
4. Fasting Blood Sugar
    Post Prandial Blood Sugar
5.LIPID PROFILE
6. Serum CK-MB
7. Chest-X-Ray 
8. Electrocardiogram:
9. Echocardiogram:
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ABBREVIATIONS:
STEMI- ST Elevation Myocardial Infarction
NSTEMI-Non ST Elevation Myocardial Infarction
MI-Myocardial Infarction
BMI-Body Mass Index
CHF-Congestive heart Failure
CAD-Coronary Artery Disease
Wgt-Weight in kilogram
Hgt-Height in centimeter
CP-Chest Pain
Pal-Palpitation
Dys-Dyspnoea
EP-Epigastric Pain
Nau-Nausea
Vomi-Vomiting
Radi-Radiating pain
Oth-Other symptoms
HT-Hypertension
DM-Diabetes Mellitus
KS-Killip score
JVP-Jugular Venous Pressure
PE-Pedal Edema
Al-Alcohol
Smo-Smoking
BP-Blood Pressure
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AI Shift-Apical Impulse Shift
Dyslipid-Dyslipidemia
THrombo-Thrombolysis
T-Thrombolysed
N-Not thrombolysed
MR-Mitral Regurgitation
CK-MB-Creatine Kinase
ECG-Electrocardiogram
AWMI-Anterior Wall Myocardial Infarction
ASMI-Antero Septal Myocardial Infarction
LMI-Lateralwall Myocardial Infarction
IWMI-Inferior Wall Myocardial Infarction
PWMI-Posterior Wall Myocardial Infarction
RVMI-Right Ventricular Myocardial Infarction
CKD-Chronic Kidney Disease
LDL-C-Low Density Lipoprotein Cholesterol
HDL-C-High Density Lipoprotein Cholesterol
SLE-Systemic Lupus Erythematosus
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S.NO IP
NO.
Age Wgt Hg
t
BMI                                      SYMPTOMS DM
C
P
Pal D
y
s
EP Nau Vomi Radi. oth
1 27549 54 71 15
3
30.3 N Y Y N Y Y Y N Y
2 27584 60 67 14
0
34.1 Y N N N N N N N N
3 27708 76 55 14
4
26.5 Y y Y N N N N N Y
4 27865 67 56 14
0
28.6 Y N N Y Y Y Y N N
5 27940 68 53 15
1
23.2 N Y Y N N N N N Y
6 28137 76 70 14
3
34.2 Y N Y N N N N N Y
7 28512 61 54 15
2
23.4 Y N N N N N N N N
8 28520 56 58 13
9
30.0 Y N N N N N N N N
9 28580 78 66 14
1
33.2 N Y Y N Y Y N N Y
10 28583 64 56 15
5
23.3 Y N N N N N N N N
11 28586 61 62 14
6
29.1 Y N N Y N N N N Y
12 28733 43 54 14
3
26.4 Y y N N N N Y N N
13 28753 76 47 15
1
20.6 Y N Y N Y N N N Y
14 28882 63 54 14
1
27.1 Y N N N N N N N Y
15 29020 79 63 15
0
28.0 Y N N N N N N N N
16 29109 66 55 14
7
25.5 N Y Y Y N N N N Y
17 29374 58 79 14
3
38.6 Y N N N N N Y N N
18 29439 86 54 14
8
24.7 Y N N N Y Y N N N
19 29529. 67 59 14
4
28.5 Y N N N N N N N N
20 29622 54 53 14
0
27.0 Y y Y N N N Y N Y
21 29789 77 68 14
2
33.8 Y N N N N N N N N
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22 30098 53 70 14
1
35.2 Y N Y N N N N N N
23 30115 62 57 14
2
28.3 Y Y N N N N N N Y
24 30240 56 66 13
8
34.7 Y N N Y N N N N N
25 30575 57 45 15
2
19.5 N Y Y N N N Y N N
26 30601 81 46 13
7
24.5 Y N Y N N N N N Y
27 30663 68 69 15
3
29.5 Y N N N Y Y N N N
28 30699 90 70 14
1
35.2 Y N N N N N N N N
29 30725 67 49 13
9
25.4 N y Y N N N N N Y
30 31125 79 63 14
2
31.2 Y N Y N N N N N N
MASTER CHART
S. IP Age Wgt HBMI              SY
MPTOMS
HT
CP Dys EP Vom
i
Radi
31 3122
2
47 52 1 27.3 Y Y N N N Y
32 3135
1
48 59 1 28.1 Y N Y N Y N
33 3144
6
61 59 1 33.4 Y N N N N N
34 3154
8
76 46 1 22.2 N Y N N N N
35 3170
8
65 64 1 34.1 Y N N Y Y Y
36 3172
1
70 57 1 30.4 Y N N N N N
37 3205
9
63 49 1 25.7 N Y N N N N
38 3211
0
55 52 1 28.5 Y N Y N N Y
39 3211
5
68 63 1 36.1 Y N N N N N
40 3221
7
53 61 1 29.0 Y N N N Y N
41 3226
6
77 47 1 23.6 Y N N Y N N
42 3243
8
76 64 1 28.8 N Y N N N N
43 3275
5
52 65 1 36.2 Y N N N N Y
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44 3278
3
80 57 1 29.5 N Y N N Y N
45 3358
7
76 61 1 35.6 Y Y N N N N
46 3360
0
48 43 1 19.4 Y N N N N N
47 3363
1
61 59 1 31.0 Y N Y N N N
48 3363
9
44 60 1 33.4 Y Y N Y N Y
49 3365
9
76 54 1 23.7 Y N N N Y N
50 3378
7
62 66 1 30.1 Y N N N N N
51 3412
1
79 59 1 33.4 Y N N N N N
52 3448
1
77 55 1 25.1 N Y N N N Y
53 3477
9
65 67 1 28.3 Y N N N N N
54 3503
4
49 50 1 22.5 Y N N Y Y N
55 3523
7
82 54 1 30.1 N Y N N N Y
56 3531
4
47 77 1 40.4 Y N N N N N
57 3569
5
82 62 1 34.5 N Y N N Y N
58 3599
5
55 64 1 33.1 Y N N N N Y
59 3600
8
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60 3612
5
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S.no IP
No
Age Wgt HBMI                    
SYMPTOM
S
HT 
CP Dys EP Vomi Radi
61 3637
7
76 60 1 33.9 Y Y Y Y N Y
62 3652
4
46 55 1 24.8 Y N N N Y N
63 3656
3
79 59 1 28.5 Y N N N N Y
64 3658
7
51 52 1 26.5 Y N N N Y N
65 3663
8
61 45 1 19.5 N Y N N N Y
66 3711
7
56 66 1 28.9 Y N Y N N N
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3
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1
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1
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6
48 61 1 29.0 Y N N N Y Y
71 3781
6
90 72 1 39.5 N Y N Y N N
72 3797
8
42 57 1 24.7 Y N N N N Y
73 3813
8
64 55 1 28.9 Y Y N N N N
74 3824
6
70 65 1 30.5 Y N N N N N
75 3850
6
79 66 1 35.7 N y N N Y Y
76 3867
5
47 49 1 20.1 Y Y Y N N N
77 3876
4
77 54 1 27.2 Y N N N N N
78 3900
8
64 63 1 28 Y N N Y N Y
79 3901
3
69 60 1 34.96 N y N N N N
80 3912
7
78 55 1 25.5 Y N N N Y N
81 3938
6
49 63 1 28.4 Y Y N N N Y
82 3948
4
80 70 1 35.2 Y N N N N N
83 3960
3
72 57 1 25 Y N N N N Y
84 3979
4
65 54 1 30.5 Y N N N N N
85 3981
2
81 68 1 34.7 N Y N N Y Y
86 3994
8
51 51 1 27.9 Y N N Y N Y
87 4011
6
69 62 1 29.5 Y N N N N N
88 4014
6
76 69 1 33.8 Y N N N N Y
89 4027
6
68 56 1 25.2 N Y Y N N N
90 4069
0
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S.no BP JVP PE A
I 
S3 S4 Creps Whee
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Thro LDL-C CK-
MB
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21 174/
108
N N N N N Y Y T 163 125
22 118/
76
N N N N N N N T 166 147
23 160/
102
N N N Y Y Y N T 119 139
76
24 126/
80
N Y N N N N N N 168 134
25 124/
78
N N N N N N N T 170 128
26 166/
103
N N Y Y N Y N N 154 190
27 128/
80
Y N N N N N N T 162 94
28 180/
100
N N N N N N N N 98 144
29 130/
82
N N N N N N N N 144 137
30 112/
72
N N N Y N Y N T 169 133
S.no BP JVP PE A
I 
s
h
if
t
S3 S4 Creps Whee
ze
Thro LDL-C CK-
MB
31 108/
70
N N N Y N Y N N 167 109
32 168/
90
N Y N N N N N T 154 164
33 124/
80
Y N Y N N N N N 170 113
34 130/
80
N N N N N Y Y N 116 84
35 160/
100
N N N N N N N T 181 86
36 114/
78
N N N N N N N T 164 96
37 84/5
4
N Y N Y N Y N T 149 101
38 120/
80
N N N N N N N T 163 156
39 132/
82
N N N N N N N T 102 137
40 150/
96
N N Y N N Y N N 139 113
41 120/
84
Y Y N N N N N N 170 115
42 116/
80
N N N N N N N T 169 98
43 170/
104
N N N N N N N T 131 130
44 124/
80
N N N Y Y Y Y N 175 114
45 130/
84
N N N N N N N T 174 146
77
46 108/
74
N N N N N N N T 93 121
47 188/
100
N N N N N N N N 176 134
48 126/
80
N Y N N N Y N N 162 140
49 118/
80
Y N Y N N N N N 145 109
50 160/
104
N N N N N N N T 177 114
51 116/
76
N N N Y N Y N T 170 105
52 120/
82
N N N N N N N N 169 151
53 158/
98
N Y N N N N N N 117 135
54 126/
74
N N N N N N N N 174 140
55 124/
76
Y N N N N N N T 165 128
56 170/
100
N N N Y Y Y Y T 134 134
57 116/
70
N N Y N N N N N 166 156
58 124/
82
N N N N N N N N 85 139
59 122/
78
Y Y N N N Y N T 170 109
60 110/
70
N N N Y N N N N 164 103
S.no BP JVP PE A
I 
s
h
if
t
S3 S4 Creps Whee
z
Thro
m
LDL-C CK-
MB
61 150/
100
N Y N N N N N T 134 113
62 114/
76
N N Y Y N Y N T 165 108
63 122/
78
N N N N N N N N 119 159
64 158/
96
N N N N N N N T 161 146
65 112/
70
Y N N Y N Y N N 152 123
66 126/
80
N Y N N N N N N 178 116
67 188/
110
N N N N N Y Y N 169 107
78
68 120/
80
N N Y N N N N T 142 146
69 110/
74
N N N N N N N N 107 136
70 128/
82
N N N Y N Y N T 133 126
71 178/
100
N Y N N N N N N 181 119
72 136/
86
N N Y N N N N T 146 154
73 130/
76
N Y N N N N N N 166 140
74 148/
100
N N N Y Y Y N T 96 124
75 110/
76
N N N N N N N T 163 139
76 120/
70
N N N N N N N N 136 190
77 130/
78
Y Y N Y N Y N N 174 141
78 150/
98
N N N N N N N N 180 201
79 118/
78
N N N N N N N T 141 125
80 110/
76
N N Y N N N N T 117 78
81 80/6
0
Y N N Y N Y N T 168 107
82 122/
80
N N N N N N N N 177 134
83 166/
106
N Y N N N N N N 147 165
84 126/
86
N N N Y N Y N T 101 101
85 120/
74
N N N N N N N T 174 74
86 158/
104
N N N N N Y N T 139 129
87 114/
70
N N Y Y N Y Y N 164 245
88 116/
76
N Y N N N N N T 116 165
89 160/
102
N N N N N N N N 136 141
90 128/
78
N N N N N Y N T 173 115
79
